Duration of anticoagulant therapy for venous thromboembolism.
نویسندگان
چکیده
The Medical Journal of Australia ISSN: 0025729X 15 June 2009 190 12 659-660 ©The Medical Journal of Australia 2009 www.mja.com.au Editorials days with unfractionated heparin, low-molecular-wei fondaparinux, prevents thrombus progression and re of recurrent VTE and death during the acute ph treatment is continued beyond the acute phase, wa the risk of recurrent VTE but increases the risk of requires frequent laboratory monitoring, which is inc patients. Thus, decisions regarding the optimal dur The risk of bleeding, as well as patient preferences, must be considered when deciding duration of warfarin therapy
منابع مشابه
Recurrent Venous Thromboembolism as the Initial Clinical Presentation of Gastric Cancer: A Case Report
Pulmonary thromboembolism (PTE) is a clinically critical disease, misdiagnosis or delayed diagnosis of which can lead to increased rate of mortality. For prevention of recurrence of PTE, recognition of its risk factors or underlying diseases is of great importance. PTE is common in patients with cancer and has high morbidity and mortality rates. Although cancer is a lethal condition, PTE accele...
متن کاملTreatment of venous thromboembolism in cancer patients.
The occurrence of venous thromboembolism complicates the management of the patient with malignant disease because of the need for anticoagulant therapy. Cancer patients have an ongoing thrombotic stimulus due to the underlying cancer and its associated treatments, but are also considered to be at increased risk for anticoagulant-related bleeding. In recent years, the results of clinical trials ...
متن کاملRecurrence of idiopathic thromboembolism during anticoagulant therapy.
Patients with acute pulmonary embolism and venous thromboembolism are usually treated with anticoagulant therapy for at least 3 months as the optimum duration. A patient with recurrent idiopathic venous thromboembolism at the eighth month during anticoagulation (warfarin to target international normalized ratio of 2.0-3.0) is described. The case suggests that patients with idiopathic venous thr...
متن کاملDabigatran etexilate - A novel oral anticoagulant for bleeding complications
Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. Anticoagulation is a major intervention for the management of arterial and venous thromboembolic events. Dabi...
متن کاملبررسی میزان استفاده از عوامل پیشگیری کننده ترومبوآمبولی وریدی در بخش جراحی یک بیمارستان خصوصی در تهران
ABSTRACT Venous thromboembolism (VTE) is one of the most common problems involves patients in a surgical ward. This problem will be preventable, if we consider risk factors in these patients and use preventive measurments on time. To evaluae our colleages in surgical ward for using preventive medications and physical methods in prevention of venous thromboembolism, we conducted this cr...
متن کاملDuration of anticoagulation treatment in patients with venous thromboembolism.
Deep vein thrombosis and pulmonary embolism are clinical manifestations of venous thromboembolism, and they necessitate anticoagulant therapy in most cases. The duration of treatment is predicated on a balance between the risk of recurrent disease and the risk of bleeding inherent to anticoagulant therapy. It is important that physicians are aware of evidence-based guidelines that can enhance d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Medical journal of Australia
دوره 190 12 شماره
صفحات -
تاریخ انتشار 2009